Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Life Science Innovation Northwest 2025
12 slides from Cocrystal Pharma's conference presentation, April 2025
Slide 1: Potent antivirals to combat some of the most serious diseases facing humanity
Potent antivirals to combat some of the most serious diseases facing humanity Life Science Innovation Northwest April 2025 Nasdaq: COCP www.cocrystalpharma.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our ability to deliver significant growth from our multiple clinical assets, our plans for a human challenge study in 2025, the resul
Slide 3: About Cocrystal Pharma
About Cocrystal Pharma Advancing programs in high-value antiviral drug targets • Norovirus • Influenza • Coronavirus and respiratory viruses Applying powerful, proprietary Drug candidates with clinically validated mechanisms of action drug discovery platform • Effectively cure viral diseases technol
Slide 4: Cocrystal's Structure-Based Drug Discovery Platform Technology
Cocrystal’s Structure-Based Drug Discovery Platform Technology For Pan-Viral Direct Acting Antiviral Development Cocrystal pan-viral inhibitors target highly Cocrystal technology uniquely offers: conserved viral protease active site SARS-Cov-2 SARS-Cov-1 MERS-CoV Norovirus 1 Systematic analysis of d
Slide 5: Robust Pipeline Addressing Unmet Medical Needs
Robust Pipeline Addressing Unmet Medical Needs Multiple clinical assets poised to deliver significant growth Program Candidate Discovery Preclinical Phase 1 Phase 2 Phase 3 Norovirus & Oral Pan-viral Coronavirus protease inhibitor CDI-988 Norovirus Replication inhibitors Respiratory viruses Pan-vira
Slide 6: Norovirus Infection: No Approved Treatments or Vaccines Available
Norovirus Infection : No Approved Treatments or Vaccines Available Cruise ships Restaurants Norovirus Nursing homes Military Schools Bronson Norwalk Elementary School 6
Slide 7: Norovirus Viral Gastroenteritis Represents a Large Global Market: $72.7 Billion by 2032
Norovirus Viral Gastroenteritis Represents a Large Global Market: $72.7 Billion by 2032 No treatment or vaccines available Cocrystal’s pan-viral protease inhibitor, CDI-988: • First-in-class antiviral for norovirus • Potential for both prevention and treatment • Phase 1 SAD and MAD studies complete
Slide 8: Big Surge of Norovirus Outbreaks in 2024-2025 After COVID-19 Pandemic
Big Surge of Norovirus Outbreaks in 2024-2025 After COVID-19 Pandemic 2024-2025 norovirus outbreaks 8 Reference: Science, 13 January 2025 8 Confidential
Slide 9: Norovirus GII.17 Variants Become Dominant
Norovirus GII.17 Variants Become Dominant: >70% Responsible For Recent Norovirus Outbreaks GII.17 COVID GII.4 COVID https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.39.2400625 9 9 Confidential
Slide 10: Pan-Viral Protease Inhibitor CDI-988 For Norovirus and COVID
Pan-Viral Protease Inhibitor CDI-988 For Norovirus GII.4 and GII.17 and COVID (A) SARS-CoV-2 • First-in-class antiviral for norovirus CDI-988 • Developed using Cocrystal’s proprietary drug discovery platform technology • Binds to a highly conserved region required for viral proteases (B) Norovirus •
Slide 11: Oral Pan-viral Protease Inhibitor CDI-988 Showed Favorable Safety and Tolerability
Oral Pan-viral Protease Inhibitor CDI-988 Showed Favorable Safety and Tolerability • Single-center, randomized, double-blind, placebo-controlled • Single-ascending dose (SAD) and Multiple-ascending dose (MAD) cohorts • Healthy adult volunteers (18 – 55 years old) Phase 1 study summary • All dose coh
Slide 12: Investment Highlights
Investment Highlights • Targeting multibillion-dollar, global markets for the treatment of acute and pandemic viral diseases • Proprietary structure-based drug discovery platform technology provides opportunity for discovery and development of novel, broad-spectrum drug candidates • Advancing multip
Cocrystal Pharma — Life Science Innovation Northwest 2025 on 6ix